Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Long-Term Investments: 2019-2025

Historic Long-Term Investments for BridgeBio Pharma (BBIO) over the last 3 years, with Sep 2025 value amounting to $92.2 million.

  • BridgeBio Pharma's Long-Term Investments fell 42.55% to $92.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $92.2 million, marking a year-over-year decrease of 42.55%. This contributed to the annual value of $143.7 million for FY2024, which is N/A change from last year.
  • Per BridgeBio Pharma's latest filing, its Long-Term Investments stood at $92.2 million for Q3 2025, which was down 14.66% from $108.0 million recorded in Q2 2025.
  • BridgeBio Pharma's 5-year Long-Term Investments high stood at $160.4 million for Q3 2024, and its period low was $60.7 million during Q2 2021.
  • Moreover, its 2-year median value for Long-Term Investments was $122.6 million (2024), whereas its average is $124.9 million.
  • As far as peak fluctuations go, BridgeBio Pharma's Long-Term Investments skyrocketed by 254.17% in 2021, and later tumbled by 42.55% in 2025.
  • Over the past 3 years, BridgeBio Pharma's Long-Term Investments (Quarterly) stood at $60.7 million in 2021, then reached $143.7 million in 2024, then crashed by 42.55% to $92.2 million in 2025.
  • Its Long-Term Investments was $92.2 million in Q3 2025, compared to $108.0 million in Q2 2025 and $128.2 million in Q1 2025.